Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

An Optimized PatchMatch for multi-scale and multi-feature label fusion

  • Giraud, Rémi
  • Ta, Vinh-Thong
  • Papadakis, Nicolas
  • Collins, Louis
  • Coupé Pierrick
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
  • Alzheimers Dis Neuroimaging Initia
Automatic segmentation methods are important tools for quantitative analysis of Magnetic Resonance Images (MRI). Recently, patch-based label fusion approaches have demonstrated state-of-the-art segmentation accuracy. In this paper, we introduce a new patch-based label fusion framework to perform segmentation of anatomical structures. The proposed approach uses an Optimized PAtchMatch Label fusion (OPAL) strategy that drastically reduces the computation time required for the search of similar patches. The reduced computation time of OPAL opens the way for new strategies and facilitates processing on large databases. In this paper, we investigate new perspectives offered by OPAL, by introducing a new multi-scale and multi-feature framework. During our validation on hippocampus segmentation we use two datasets: young adults in the ICBM cohort and elderly adults in the EADC-ADNI dataset. For both, OPAL is compared to state-of-the-art methods. Results show that OPAL obtained the highest median Dice coefficient (89.9% for ICBM and 90.1% for EADC-ADNI). Moreover, in both cases, OPAL produced a segmentation accuracy similar to inter-expert variability. On the EADC-ADNI dataset, we compare the hippocampal volumes obtained by manual and automatic segmentation. The volumes appear to be highly correlated that enables to perform more accurate separation of pathological populations. (C) 2015 Elsevier Inc. All rights reserved., This study has been carried out with financial support from the French State, managed by the French National Research Agency (ANR) in the frame of the Investments for the future Program IdEx Bordeaux (ANR-10-IDEX-03-02), Cluster of excellence CPU and TRAIL (HR-DTI ANR-10-LABX-57). We also thank Tong Tong and Daniel Rueckert for providing us complete results of the methods proposed in Tong et al. (2013), Sonia Tangaro and Marina Boccardi for providing us complete results of the method proposed in Tangaro et al. (2014), and Katherine Gray and Robin Wolz for providing us complete results of the LEAP method proposed in Gray et al. (2014). Data collection and sharing for this project were funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). The ADNI is funded by the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics NV, Johnson and Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche, Schering-Plough, Synarc Inc., as well as nonprofit partners, the Alzheimer's Association and Alzheimer's Drug Discovery Foundation, with participation from the U.S. Food and Drug Administration. Private sector contributions to the ADNI are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study was coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by the Spanish grant TIN2013-43457-R from the Ministerio de Economia y competitividad, NIH grants P30AG010129, K01 AG030514 and the Dana Foundation.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Scoring by nonlocal image patch estimator for early detection of Alzheimer&apos, s disease

  • Coupé, Pierrick
  • Eskildsen, Simon F.
  • Fonov, Vladirmir S.
  • Pruessner, Jens C.
  • Allard, Michèle
  • Collins, Louis D.
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
Detection of Alzheimer's disease (AD) at the first stages of the pathology is an important task to accelerate the development of new therapies and improve treatment. Compared to AD detection, the prediction of AD using structural MRI at the mild cognitive impairment (MCI) or pre-MCI stage is more complex because the associated anatomical changes are more subtle. In this study, we analyzed the capability of a recently proposed method, SNIPE (Scoring by Nonlocal Image Patch Estimator), to predict AD by analyzing entorhinal cortex (EC) and hippocampus (HC) scoring over the entire ADNI database (834 scans). Detection (AD vs. CN) and prediction (progressive - pMCI vs. stable - sMCI) efficiency of SNIPE were studied using volumetric and grading biomarkers. First, our results indicate that grading-based biomarkers are more relevant for prediction than volume-based biomarkers. Second, we show that HC-based biomarkers are more important than EC-based biomarkers for prediction. Third, we demonstrate that the results obtained by SNIPE are similar to or better than results obtained in an independent study using HC volume, cortical thickness, and tensor-based morphometry, individually and in combination. Fourth, a comparison of new patch-based methods shows that the nonlocal redundancy strategy involved in SNIPE obtained similar results to a new local sparse-based approach. Finally, we present the first results of patch-based morphometry to illustrate the progression of the pathology., We wish to thank Dr. Robin Wolz for providing the list of ADNI subjects used in his study, which allowed us to perform the presented method comparison. We also want to thank the Canadian Institutes of Health Research (MOP-111169) and the Fonds de la recherche en sante du Quebec. Data collection and sharing for this project were funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). The ADNI is funded by the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics NV, Johnson & Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche, Schering-Plough, Synarc Inc., as well as nonprofit partners, the Alzheimer's Association and Alzheimer's Drug Discovery Foundation, with participation from the U. S. Food and Drug Administration. Private sector contributions to the ADNI are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study was coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by NIH grants P30AG010129, K01 AG030514 and the Dana Foundation and also by the Spanish grant TIN2011-26727 from the Ministerio de Ciencia e Innovacion.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

ALTEA: A Software Tool for the Evaluation of New Biomarkers for Alzheimer s Disease by Means of Textures Analysis on Magnetic Resonance Images

  • López-Gómez,Carlos
  • Ortiz-Ramón, Rafael
  • Mollá, Enrique
  • Moratal, David|||0000-0002-2825-3646
[EN] The current criteria for diagnosing Alzheimer's disease (AD) require the presence of relevant cognitive deficits, so the underlying neuropathological damage is important by the time the diagnosis is made. Therefore, the evaluation of new biomarkers to detect AD in its early stages has become one of the main research focuses. The purpose of the present study was to evaluate a set of texture parameters as potential biomarkers of the disease. To this end, the ALTEA (ALzheimer TExture Analyzer) software tool was created to perform 2D and 3D texture analysis on magnetic resonance images. This intuitive tool was used to analyze textures of circular and spherical regions situated in the right and left hippocampi of a cohort of 105 patients: 35 AD patients, 35 patients with early mild cognitive impairment (EMCI) and 35 cognitively normal (CN) subjects. A total of 25 statistical texture parameters derived from the histogram, the Gray-Level Co-occurrence Matrix and the Gray-Level Run-Length Matrix, were extracted from each region and analyzed statistically to study their predictive capacity. Several textural parameters were statistically significant (p < 0.05) when differentiating AD subjects from CN and EMCI patients, which indicates that texture analysis could help to identify the presence of AD., This work was supported in part by the Spanish Ministerio de Economia y Competitividad (MINECO) and FEDER funds under grant BFU2015-64380-C2-2-R. R.O.-R. was supported by grant ACIF/2015/078 from the Conselleria d'Educacio, Investigacio, Cultura i Esport of the Valencian Community (Spain).